Table 2.
Anticancer and antimicrobial peptide-based drugs and vaccines under clinical trials (Chiangjong et al. 2020; Håkansson et al. 2019; Niemeyer‐van der Kolk et al. 2020; Pan et al. 2019; Peek et al. 2020; "Peptides,"; Wang et al. 2018; Zhang and Yang 2022)
| Peptide | Peptide sequences | Target | Trial phase |
|---|---|---|---|
| SVN53-67/M57-KLH Peptide Vaccine | DLAQMFFCFKELEGW | Metastatic Pancreatic Neuroendocrine Tumor | Phase 1 |
| KRAS multipeptide vaccine |
Kras-G12D (KLVVVGADGVGKSALTI) Kras-61Wt (KLVVVGAGGVGKSALTI) Kras-63Wt (SALTIQLIQNHFVDE) Kras-68Wt (FLCVFAINNTKSFED) |
Pancreatic cancer | Phase 1 |
| Arginase-1 multipeptide vaccine |
ARG1-18 (AKDIVYIGLRDVDPGEHYIL), ARG1-19 (DVDPGEHYILKTLGIKYFSM),ARG1-20 (KTLGIKYFSMTEVDRLGIGK) |
Metastatic Solid Tumors | Phase 1 |
| MUC-1 peptide vaccine, MUC1 peptide-poly ICLC adjuvant vaccine | H2N-(GVTSAPDTRPAPGSTAPPAH)5-CONH2 | Breast cancer | Phase 1 |
| HER-2/neu peptide vaccine |
E75 (KIFGSLAFL) GP2 (IISAVVGIL) A37 (GVGSPYVSRLLGICL LRMK) |
Breast cancer | Phase 1 |
| HPV16 E7 peptide-based vaccine | GQAEPDRAHYNIVTF | Cervical cancer | Phase 1, Phase 2 |
| RNF43-721 | NSQPVWLCL | Colorectal cancer | Phase 1 |
| LY6K/VEGFR1/VEGFR2 multipeptide vaccine |
LY6K (RYCNLEGPPI) VEGFR1 (SYGVLLWEI) VEGFR2 (RFVPDGNRI) |
Esophageal cancer | Phase 1 |
| MAGE-3.A1 peptide-CpG 7909 adjuvant vaccine | EVDPIGHLY | Melanoma | Phase 1, Phase 2 |
| VEGFR1-1084, VEGFR2-169 |
VEGFR1 (SYGVLLWEI) VEGFR2 (RFVPDGNRI) |
Pancreatic cancer | Phase 1, Phase 2 |
| URLC10 peptides with adjuvant | RYCNLEGPPI | Lung cancer | Phase 1, Phase 2 |
| PD-L1 and Arginase 1 Dual peptide vaccine |
PD-L1Long1 (FMTYWHLLNAFTVTVPKDL) ArgLong2 (ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL) |
Myeloproliferative Neoplasms | Phase 1, Phase 2 |
| PD-L1/IDO peptide vaccine |
IO102 (DTLLKALLEIASCLEKALQVF) IO103 (FMTYWHLLNAFTVTVPKDL) |
Metastatic Melanoma | Phase 1, Phase 2 |
| IO102 peptide vaccine | DTLLKALLEIASCLEKALQVF | Squamous Cell Carcinoma | Phase 2 |
| WT 126-134 peptide vaccine | RMFPNAPYL | Leukemia | Phase 2 |
| PR1 peptide vaccine | VLQELNVTV | Leukemia | Phase 3 |
| Degarelix (LHRH antagonist) | Ac-XXXSXXLKPA-NH2 | Prostate cancer | Phase 4 |
| DPK-060 | GKHKNKGKKNGKHNGWKWWW | Staphylococcus aureus skin infection | Phase 2 |
| Omiganan | ILRWPWWPWRRK | Atopic dermatitis | Phase 2 |
| P60.4Ac | IGKEFKRIVERIKRFLRELVRPLR | Chronic suppurative otitis media | Phase 2 |
| Nal-P-113 | AKRXXGYKRKFX-NH2 | Periodontal Pathogenic infections | Phase 3 |